4D Molecular Therapeutics, Inc. (FDMT)
10.80
-1.05
(-8.86%)
USD |
NASDAQ |
Oct 23, 16:00
10.78
-0.02
(-0.23%)
After-Hours: 20:00
4D Molecular Therapeutics Profit Margin (Quarterly) : -1.93K% for June 30, 2026
Profit Margin (Quarterly) Chart
Historical Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -1.93K% |
| March 31, 2026 | -2.26K% |
| December 31, 2025 | 22.80% |
| September 30, 2025 | -63.20K% |
| June 30, 2025 | -364.4K% |
| March 31, 2025 | -342.7K% |
| December 31, 2024 | -4.97M% |
| September 30, 2024 | -1.46M% |
| June 30, 2024 | -699.1K% |
| March 31, 2024 | -115.7K% |
| September 30, 2023 | -50.76% |
| June 30, 2023 | -12.39K% |
| March 31, 2023 | -9.62K% |
| Date | Value |
|---|---|
| December 31, 2022 | -2.20K% |
| September 30, 2022 | -5.14K% |
| June 30, 2022 | -17.34K% |
| March 31, 2022 | -2.16K% |
| December 31, 2021 | -27.26K% |
| September 30, 2021 | -1.63K% |
| June 30, 2021 | -52.05% |
| March 31, 2021 | -820.3% |
| September 30, 2020 | -105.6% |
| June 30, 2020 | -417.1% |
| March 31, 2020 | -372.3% |
| December 31, 2019 | -793.8% |
| September 30, 2019 | -3.09K% |
Profit Margin Definition
Profit Margin is calculated using Net Income/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into profit. An analyst looking at profit margin might look for a higher profit margin relative to other comparable companies as well as a profit margin that is growing.
Profit Margin (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Profit Margin (Quarterly) Benchmarks
| Agenus, Inc. | -1.64% |
| Amgen, Inc. | 23.59% |
| Anika Therapeutics, Inc. | 10.15% |
| BioCryst Pharmaceuticals, Inc. | 35.92% |
| Imunon, Inc. | -- |
Profit Margin (Quarterly) Related Metrics
| Return on Equity | -41.57% |
| Return on Assets | -36.27% |
| Return on Invested Capital | -39.27% |
| Gross Profit Margin (Quarterly) | 44.75% |
| Operating Margin (Quarterly) | -2.04K% |
| Return on Net Operating Assets | -542.6% |